Weight Loss · GLP-1 Program
Clinical trials show up to 22% body weight reduction. REMEVi connects you with a licensed provider and ships compounded tirzepatide directly to your door. From $269/month on a 52-week plan ($339/mo 12-week, $379/mo monthly), all-inclusive.
The science
Tirzepatide is a dual GIP/GLP-1 receptor agonist that mimics two natural hormones to regulate appetite, metabolism, and blood sugar.
Signals the brain to eat less and feel full longer.
Slows food movement through the digestive system.
Regulates glucose and reduces cravings via GIP + GLP-1.
Activates two receptors for greater weight loss than GLP-1 alone.
Treatment plan
Provider-supervised dose escalation every 4 weeks to maximize results and minimize side effects.
Weeks 1–4
2.5 mg
Starter dose weekly
Weeks 5–8
5 mg
First therapeutic dose
Weeks 9–12
7.5 mg
Increased every 4 weeks
Weeks 13–24
10–15 mg
Titrate to maintenance
Injection method
Subcutaneous (under the skin)
Frequency
Once per week
Provider check-ins
Monthly dose adjustments
Timeline
Full 24-week program
What to expect
Weight loss milestones and what patients typically experience at each phase.
Weeks 1–4
Noticeable decrease in hunger and food cravings begins.
Weeks 5–12
Body weight reduction of 5–10% is common at this phase.
Weeks 13–24
Total body weight loss in clinical trials (SURMOUNT-1).
Ongoing
Maintenance dosing available to preserve results long-term.
Results vary based on adherence, diet, exercise, and individual metabolism. Your REMEVi licensed provider will monitor your progress and adjust dosing as needed.
All-inclusive
Unlike Hims, Ro, and Medvi — there are no hidden lab fees or add-on charges.
Prescription from a board-certified US licensed provider who reviews your full health history.
Compounded tirzepatide from a 503B-accredited pharmacy under strict quality control.
Medication shipped directly to your door in unmarked packaging. Free every month.
Care team available in English and Spanish with a 2-hour response SLA.
Regular check-ins with your care team to adjust dosage and monitor your progress.
REMEVi is a LegitScript-certified telehealth platform you can trust.
Same price every month for the length of your plan. No "first-month special." No surprise increases. The price you see is the price you pay — for as long as you are a patient.
Provider-managed weekly injection. The same compounded GLP-1 as the big-brand competitors — with bilingual care, no insurance, no surprise increases.
Daily oral semaglutide. Same clinical oversight, same bilingual care — without the needle.
Dual-agonist tirzepatide. The strongest average loss in the GLP-1 category — provider-managed, bilingual care.
¹ Clinical-trial results for semaglutide (STEP-1, NEJM 2021) and tirzepatide (SURMOUNT-1, NEJM 2022) — the active medications in REMEVi protocols, not REMEVi outcomes or guarantees. Compounded preparations are not FDA-approved and have not been studied as finished products. Individual results vary.
Compare with Semaglutide What compounded tirzepatide costs Compounded Zepbound alternative
REMEVi's semaglutide is compounded by a 503B outsourcing facility registered with the FDA — the same regulatory tier hospitals use. Compounded medications are not FDA-approved finished drug products; they are prepared under the 503A or 503B framework to USP <797> sterility standards and prescribed by a licensed provider in your state who will review the risks, benefits, and considerations with you.
FAQ
Tirzepatide is a dual GIP/GLP-1 receptor agonist medication approved for weight management. It works by reducing appetite and improving blood sugar regulation.
REMEVi prescribes compounded tirzepatide, which is not the same as, and is not a generic version of, Mounjaro® or Zepbound® (FDA-approved finished drug products manufactured by Eli Lilly). Compounded tirzepatide is a non-FDA-approved preparation prepared by a state-licensed compounding pharmacy under an individual prescription from a licensed US provider. Compounded preparations have not been clinically studied as finished products. Your licensed provider will review risks, benefits, and considerations with you before prescribing.
Starting from $269/month on our 52-week plan ($339 on 12-week, $379 monthly). All plans are all-inclusive — no hidden fees.
Clinical trials (SURMOUNT-1) showed tirzepatide at the highest dose produced up to 22% body weight loss, generally outperforming semaglutide trials. Individual results vary.
Most patients notice appetite changes in the first 2–4 weeks. Meaningful weight loss typically becomes visible by weeks 8–12.
Yes. Your REMEVi licensed provider can evaluate a transition during your consultation.
5-minute intake. Clinical review within 24 hours. Medication shipped free.
Start free consultation — from $269/moNo insurance required · Cancel anytime
